A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma

British Journal of Cancer
C BurtonD Cunningham

Abstract

The management of older patients with aggressive non-Hodgkin's lymphoma presents a challenge to the physician. Age is a poor prognostic indicator, due to reduced ability to tolerate and maintain dose-intensive chemotherapy. Generally, older patients demonstrate a lower response rate, reduced survival and increased toxicity, although the majority of large randomised trials exclude older patients. This randomised trial was conducted in patients 60 years or over to compare CHOP (cyclophosphamide 750 mg m(-2), doxorubicin 50 mg m(-2), vincristine 1.4 mg m(-2), prednisolone 100 mg) with PMitCEBO (mitoxantrone 7 mg m(-2), cyclophosphamide 300 mg m(-2), etoposide 150 mg m(-2), vincristine 1.4 mg m(-2), bleomycin 10 mg m(-2) and prednisolone 50 mg). Due to the myelosuppressive nature of these regimens, patients were also randomised to the addition of G-CSF. The formal results of this trial with long-term follow-up are now reported. Data were analysed to assess efficacy and toxicity. Overall response rate was 84% in the CHOP arm and 83% in the PMitCEBO arm, with overall response rates of 83% for the use of G-CSF and 84% for no G-CSF. At median 44 months follow-up, there was no significant difference in failure-free, progression-free or ...Continue Reading

References

Mar 1, 1976·British Journal of Preventive & Social Medicine·A M Adelstein
Dec 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J W SweetenhamJ M Whitehouse
Dec 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SurboneR C Young
Jan 1, 1985·Investigational New Drugs·L E PosnerK Cartwright
Apr 1, 1984·Journal of the American Geriatrics Society·J O Armitage, J F Potter
Jan 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V ZagonelS Monfardini
Dec 1, 1994·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M BertiniM Pini
Oct 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P SonneveldB Lowenberg
Sep 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R M MeyerG A Foster
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
May 20, 1999·Cancer Causes & Control : CCC·R J McNallyR A Cartwright
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L Balducci, G H Lyman
Feb 4, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S LimatJ Y Cahn
Jun 11, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A WunderlichUNKNOWN German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
Aug 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J K DoorduijnP Sonneveld
Oct 14, 2004·Annals of Hematology·Antonia M S MüllerMonika Engelhardt
May 4, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P FeugierB Coiffier

❮ Previous
Next ❯

Citations

Nov 1, 2011·Journal of the National Cancer Institute·Arnold L PotoskyJane C Weeks
Jan 26, 2016·Expert Opinion on Drug Safety·Gary H LymanEva Culakova
Jul 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicole M KudererGary H Lyman
Apr 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary H LymanJeffrey Crawford
Nov 15, 2016·Journal of the American Animal Hospital Association·Ashley A SmithCarlos H M Souza
Oct 27, 2006·Clinical Journal of Oncology Nursing·Patricia C Buchsel, Elaine S DeMeyer
Apr 3, 2012·British Journal of Haematology·Paul A Fields, David C Linch
Oct 10, 2008·The Cochrane Database of Systematic Reviews·Julia BohliusAndreas Engert
Dec 23, 2016·Asia-Pacific Journal of Clinical Oncology·Babak TamjidEliza A Hawkes
Jun 6, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M S AaproUNKNOWN European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.